Basel, Switzerland, Thursday, May 4, 2017 – CIS Pharma presents its ADC drug carrier technology at Swiss Biotech Day 2017, scheduled for 14:10 during the Emerging Companies Streams. CIS Pharma ADC drug carriers are based on the proprietary Cellophil® Smart Polymer technology that allows the ADCs to be custom designed for delivery of a wide array of anti-tumor agents directly to the cancerous cells. The defined objective is to improve the potency of antibody-drug conjugates. The Swiss Biotech Day is the leading biotechnology conference in Switzerland. Constantly growing, the 2017 event will bring together around 500 senior executives from the life science industry across Europe. Also see Swiss Biotech Association.
About antibody-drug conjugates
Antibody-drug conjugates, or ADCs, are a class of highly potent drugs for the treatment of cancer. ADCs are composed of an antibody that is linked to an anti-cancer payload. The conjugates target cancer cells. Due to the high affinity of the antibodies to tumor cells, the cytotoxic payload is delivered specifically to the cancer tissue, reducing harmful side effects associated with traditional chemotherapeutic agents.
About CIS Pharma AG
CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. CIS Pharma is located in the life science cluster of Basel, Switzerland. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of currently used medical treatments. For more information about the company, visit our website www.cis-pharma.com. — Discovery is our business, progress our passion.